about
The pharmacological management of osteoporosisHypercalcemia of malignancy and new treatment optionsCollapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literatureDrug-induced glomerular disease: attention required!Drug-induced glomerular disease: direct cellular injury.Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compoundConsidering renal risk while managing cancer.Pathogenesis of renal failure in multiple myeloma: any role of contrast media?Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials.Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis.Safety of drugs used in the treatment of osteoporosis.Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.Optimizing bone health and minimizing skeletal morbidity in men with prostate cancerUse of oral bisphosphonates by older adults with fractures and impaired renal functionZoledronic acid: clinical utility and patient considerations in osteoporosis and low bone massDrug-induced impairment of renal function.A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.Side effects of bone-targeted therapies in advanced breast cancer.Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in SpainSevere vitamin D deficiency among heart and liver transplant recipients.Exposure to bisphosphonates and risk of cancer: a protocol for nested case-control studies using the QResearch primary care database.Local pamidronate influences fracture healing in a rodent femur fracture model: an experimental study.Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.A single-dose study of denosumab in patients with various degrees of renal impairment.Bisphosphonates for the treatment of osteoporosis: insights for clinicians.Study of Adverse Effect Profile of Parenteral Zoledronic Acid in Female Patients with OsteoporosisAcute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) projectZoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patientsFeasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology GroupClinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinionsPlant-derived anticancer agents: a promising treatment for bone metastasis.Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement.Safety of long-term bisphosphonate therapy for the management of osteoporosis.Pain management in hypertrophic pulmonary osteoarthropathy: an illustrative case and review.Progress in the treatment of bone metastases in cancer patients.The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.Bisphosphonates use in children.Osteoporosis treatment: why ibandronic acid?Renal safety in patients treated with bisphosphonates for osteoporosis: a review.Therapy for patients with CKD and low bone mineral density.
P2860
Q24605290-152AE650-A7E2-496A-9A44-BBE81AF6E00CQ26775300-E81290C8-1A0E-41DA-88B1-4589D06A3493Q26801348-C3E01465-FE5A-4F7A-BA64-A4D1413F4D0EQ26829793-31021B90-377C-41B4-98E9-1B8745165467Q27692666-F7B79375-A064-4F31-BA2B-40AA72AC2D73Q28543939-C71BF44F-71C3-4EA0-92BE-24243BE92234Q30234338-1F6A25ED-585D-4EC4-B6C7-DA35E8BA508BQ33616884-3F3B84B2-D6E6-4ED7-B8B1-1D1496A255E8Q33727640-0B8B3A99-1A96-458E-9C0B-5014671C08C4Q33769962-61E41D1B-4F55-434E-AF8C-8E1C399E8543Q33949479-A3763AA0-83EC-4F84-83DC-2C7A1B6B7869Q34018048-147C65BB-D6D6-4458-A9A4-2437316203F3Q34023510-16290BDD-B1CA-4423-BB68-3BD3B123DD85Q34220843-F6E550D1-CAA0-4784-B53F-7E4AAD971EF9Q34389524-3057A8D7-8134-4AB6-B7E9-8F261BBBAEA1Q34731462-DEA27B71-58E1-414D-9EA8-A3464B499C8CQ35050731-2787C6C7-7646-4467-9143-E4CD3BD1C7EBQ35066955-86932728-99A3-443B-A0F9-DC1D2FCA2AC6Q35087883-2C590DB4-DEF7-48E8-9415-D838B9E726C9Q35091888-BCC78F19-AEBF-4AA2-B6FF-97F47EDDCDC2Q35753917-9D3AC35C-6A77-41D6-8DC5-BE5286E58B59Q36047570-F3E78D34-27DE-4121-B40F-70F0CE7BA21AQ36209159-7870A76B-D95B-4259-91F1-1FA3E4D6CAADQ36420481-78A92C66-341D-4CFD-B438-02A54FC950BCQ36443681-93B87E99-1B72-41A0-86EA-22BEED195E26Q36541909-FE95B456-1540-4D09-85FB-727285BF7EDDQ36678173-DD4DC23A-9515-4B31-A6AF-A9E78EBE4DCDQ36846801-2DF3A854-3E29-435B-A2E4-300F6ECA96BCQ36946864-CFBC8EAE-0D63-4795-B0F8-763C3550C276Q37058784-907AE154-14EF-4013-B8B4-933BBE6EB091Q37640924-D56B0027-38DC-4132-A7E8-589E6A764B26Q37786856-B957A106-A730-4899-A9CB-EE6AF86E6FA3Q37866764-1C91FA85-9503-4668-BD23-E7B6656FBC8CQ37945593-40AFCF3B-7A16-4377-B028-FEA417FBABA1Q38002450-BBF3357A-69B5-459A-B8FD-E4AFA4D32E04Q38006918-E0AD770D-DC7E-4E5D-94A2-869286C8270DQ38039262-028629AB-AF50-4794-905E-C5F186C67A32Q38104738-26D5F741-A6DC-4493-8D54-67A315E6CE47Q38125952-5D7579ED-00A6-41D5-963E-65049139EBDCQ38150099-478C0C95-A78B-4C46-8026-BD886E2F7B9C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bisphosphonate nephrotoxicity.
@en
Bisphosphonate nephrotoxicity.
@nl
type
label
Bisphosphonate nephrotoxicity.
@en
Bisphosphonate nephrotoxicity.
@nl
prefLabel
Bisphosphonate nephrotoxicity.
@en
Bisphosphonate nephrotoxicity.
@nl
P356
P1433
P1476
Bisphosphonate nephrotoxicity.
@en
P2093
Glen S Markowitz
Mark A Perazella
P2888
P304
P356
10.1038/KI.2008.356
P407
P577
2008-08-06T00:00:00Z